1993. Ceftaroline Fosamil for the Treatment of Intensive Care Unit Patients With Pneumonia: CAPTURE Study Experience
Session: Poster Abstract Session: Clinical: Respiratory Track
Saturday, October 7, 2017
Room: Poster Hall CD

Background: Pneumonia remains a leading cause of intensive care unit (ICU) admission and is associated with substantial morbidity and mortality. Ceftaroline fosamil is approved for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia (CABP). CAPTURE is a retrospective, multicenter study describing the contemporary clinical use of ceftaroline fosamil in the US. The clinical experience in patients with pneumonia (per physician diagnosis) treated in the ICU with ceftaroline fosamil is presented.

Methods: Data including patient demographics, medical history, disease characteristics, antibiotic use, pathogens isolated, and clinical outcome were collected from 2011–2015 for patients with CABP and from 2013–2015 for patients with hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP) or healthcare-associated pneumonia (HCAP), by review of randomly ordered patient charts (ceftaroline-treated) from 62 participating sites in the US. Descriptive statistics were used to analyze the data.

Results: In total, 476 patients with pneumonia were treated with ceftaroline fosamil in the ICU (CABP, 337; HAP/VAP, 51; HCAP, 88). Baseline demographics are in Figure 1. A pathogen was isolated in 61% of the cases (291/476). Of those, methicillin-resistant Staphylococcus aureus (MRSA) was the most common (68.7%, 200/291). Antibiotics were administered before ceftaroline fosamil treatment in 85.3% of the patients. Monotherapy was used in 37.6% of patients. Mean (SD) duration of ceftaroline fosamil therapy was 7.0 (4.4) days; median (range) was 6.0 (1.0–31.0) days. Mean (SD) length of stay for all cases was 13.6 (18.3) days with a median (range) of 9.0 (1.0–263.0) days. Most patients received a dose every 12 hours (72%). Overall clinical success was 72.5% (345/476). Clinical success rates assessed by treatment regimen, antibiotic history, pathogen, and diagnosis are summarized in Figure 2. Clinical success among patients isolated with MRSA was 63.5% (127/200).

Conclusion: Clinical success rates were high for patients with pneumonia requiring ICU admission who were treated with ceftaroline fosamil, including those who received prior antibiotic treatment.

Michael Nowak, PharmD1, Jennifer M. Hayes, PharmD1, Angelina Jiang, MS1, Keith S. Kaye, MD, MPH2 and George Udeani, PharmD, DSc, FCP, FCCP3, (1)Allergan plc, Jersey City, NJ, (2)University of Michigan Medical School, Ann Arbor, MI, (3)Corpus Christi Medical Center and Texas A&M University Health Sciences Center, Corpus Christi, TX

Disclosures:

M. Nowak, Allergan plc: Employee , Salary

J. M. Hayes, Allergan plc: Employee , Salary

A. Jiang, Allergan plc: Employee , Salary

K. S. Kaye, Allergan plc: Consultant , Consulting fee

G. Udeani, Allergan plc: Investigator , Research grant

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.